Neurvati operates a collaborative platform focused on advancing drug candidates for neurological and psychiatric disorders. The company employs a search-evaluate-invest-develop strategy to optimize the development and commercialization of novel neuroscience therapies. This approach leverages deep expertise and resources to move promising product candidates through clinical and regulatory milestones.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective treatments for neurological and psychiatric disorders is challenging due to the complexity of the brain and the limited understanding of the underlying biological mechanisms. Traditional drug development approaches often face high failure rates and long timelines, resulting in unmet needs for patients with these conditions.
Solution
Neurvati Neurosciences is a biotechnology company that employs a search-evaluate-invest-develop model to advance novel therapies for neurological and psychiatric disorders. The company assesses advances in neuroscience research, reviews pre-clinical and clinical data, and confirms the commercial potential of promising product candidates. Neurvati establishes fit-for-purpose subsidiary companies to optimize the development of neuroscience therapies.
Target Audience
Neurvati's primary target audience includes individuals and families affected by neurological and psychiatric disorders, as well as strategic partners in neuroscience research and product development.
Features
- Search-evaluate-invest-develop model for identifying and advancing promising therapies
- Focus on neurological and psychiatric disorders
- Subsidiary company (GRIN Therapeutics) focused on GRIN-related disorders and pediatric epilepsy
- Radiprodil: Phase 1B clinical trial for treatment of GRIN-related disorders
- Radiprodil: Astroscape Clinical Trial for treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II
- Radiprodil: FDA Orphan Drug Designation for the treatment of GRIN-Related Neurodevelopmental Disorder
- Radiprodil: FDA Breakthrough Therapy Designation
- Radiprodil: PRIME Designation from EMA for treatment of GRIN-Related Neurodevelopmental Disorder